- Specialist drug developer ImmuPharma booked a full-year loss owing to continued R&D spending.

Pre-tax losses for the year through December amounted to £8.0m, compared to losses of £7.0m on-year.

Results of a clinical trial last year indicated that while the company's Lupuzor treatment demonstrated a superior response rate over placebo, the high response rate in the placebo group did not allow statistical significance to be reached.

'Following on from the Phase III results, we are focused on progressing Lupuzor and the P140 autoimmune platform, chairman Tim McCarthy said.

'Our plans to combine and either divest, spin off or license Elro Pharma and Ureka are planned to unlock value for shareholders.'

'We look forward to reporting on these developments in the coming months.'

At 2:00pm: [LON:IMM] ImmuPharma PLC share price was -0.44p at 9.88p

Story provided by